Hong Kong innovative drug concept stocks collectively opened lower, BeiGene (06160.HK) opened 3.5% lower, Tiger medicine (03347.HK), Kangfang biological (09926.HK) opened more than 2% lower, Fosun medicine (02196.HK) opened 1.91% lower.
Hong Kong biomedical stocks fell again in the afternoon, Junshi Biosciences (01877.HK), Kailaiying (06821.HK) fell more than 7%, Nuocheng Jianhua (09969.HK) fell more than 4.5%, drug combination (02268.HK), Tiger medicine (03347.HK), Kangfang biological (09926.HK) fell more than 3%.
Hong Kong stocks biomedical concept continued to decline in the afternoon, Tiger medicine (03347.HK) fell more than 6%, Junshi Biosciences (01877.HK), WuXi PharmaTech (02359.HK), Zaiding medicine (09688.HK), BeiGene (06160.HK) and other stocks fell.
Most of the biotechnology stocks in Hong Kong stocks strengthened, Kangsinuo Biological (06185.HK) rose more than 10%, BeiGene (06160.HK) rose more than 6%, Nuocheng Jianhua (09969.HK) rose more than 4%, Tiger Pharmaceutical (03347.HK) rose more than 3%.
港股生物技术股多数走强,康希诺生物(06185.HK)涨超10%,百济神州(06160.HK)涨超6%,诺诚健华(09969.HK)涨超4%,泰格医药(03347.HK)涨超3%。
Hong Kong stocks CXO concept stocks initially pulled up, WuXi Bio (02269.HK) rose more than 9%, Zhaoyan New Drug (06127.HK), WuXi PharmaTech (02359.HK) rose more than 4%, Tiger Pharmaceutical (03347.HK) rose more than 3%.
港股CXO概念股盘初拉升,药明生物(02269.HK)涨超9%,昭衍新药(06127.HK)、药明康德(02359.HK)涨超4%,泰格医药(03347.HK)涨超3%。